Prevalence of Immune Thrombocytopenia Purpura in Wasit Province
DOI:
https://doi.org/10.31185/wjps.455Keywords:
immune thrombocytopenia purpura, ITP, age, gander, chronic, acuteAbstract
A lower than normal platelet count is a hallmark of the acquired autoimmune disease immune thrombocytopenic purpura (ITP). This autoimmune disease is characterized by low platelet counts, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Additionally, it inhibits the production of platelets, which can be affected by drugs, infections, cancer, or other autoimmune disorders. Immune thrombocytopenia purpura can be classified into two types: acute and chronic. The acute type, which affects both sexes and typically manifests in childhood, may be brought on by a viral infection, Conversely, the chronic form, more common in women than in males, can affect adults of any gender and is not always associated with a virus infection . Immune thrombocytopenic purpura is a heterogeneous disease with varying biological behavior in terms of clinical outcome and response to treatment ,Better results are shown in children with the condition, but worse results are seen in adults.
References
J. V. AA and N. Gupta, “ITP-Immune Thrombocytopenic Purpura,” 2019.
G. Kistangari and K. R. McCrae, “Immune thrombocytopenia,” Hematol. Clin., vol. 27, no. 3, pp. 495–520, 2013.
C. M. Bennett et al., “Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants,” Pediatr. Blood Cancer, vol. 65, no. 1, p. e26736, 2018.
G. Moulis, A. Palmaro, J.-L. Montastruc, B. Godeau, M. Lapeyre-Mestre, and L. Sailler, “Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France,” Blood, J. Am. Soc. Hematol., vol. 124, no. 22, pp. 3308–3315, 2014.
T. Zitek, K. Pagano, Y. Singh, O. Mechanic, and D. Farcy, “283 Trauma Team Activation Fees Vary Widely Based on Region and Hospital Type,” Ann. Emerg. Med., vol. 80, no. 4, pp. S122–S123, 2022.
D. Provan and A. C. Newland, “Current management of primary immune thrombocytopenia,” Adv. Ther., vol. 32, pp. 875–887, 2015.
G. H. Frydman, N. Davis, P. L. Beck, and J. G. Fox, “Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: a review and the role of biogeography,” Helicobacter, vol. 20, no. 4, pp. 239–251, 2015.
F. Angum, T. Khan, J. Kaler, L. Siddiqui, and A. Hussain, “The prevalence of autoimmune disorders in women: a narrative review,” Cureus, vol. 12, no. 5, 2020.
T. Zitek, L. Weber, D. Pinzon, and N. Warren, “Assessment and management of immune thrombocytopenia (ITP) in the emergency department: current perspectives,” Open Access Emerg. Med., pp. 25–34, 2022.
J. M. Despotovic and A. B. Grimes, “Pediatric ITP: is it different from adult ITP?,” Hematol. 2014, Am. Soc. Hematol. Educ. Progr. B., vol. 2018, no. 1, pp. 405–411, 2018.
P. E. Abrahamson, S. A. Hall, M. Feudjo‐Tepie, F. S. Mitrani‐Gold, and J. Logie, “The incidence of idiopathic thrombocytopenic purpura among adults: a population‐based study and literature review,” Eur. J. Haematol., vol. 83, no. 2, pp. 83–89, 2009.
M. A. Feudjo‐Tepie, N. J. Robinson, and D. Bennett, “Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal,” J. Thromb. Haemost., vol. 6, no. 4, pp. 711–712, 2008.
J. B. Segal and N. R. Powe, “Prevalence of immune thrombocytopenia: analyses of administrative data,” J. Thromb. Haemost., vol. 4, no. 11, pp. 2377–2383, 2006.
M. Perera and T. Garrido, “Advances in the pathophysiology of primary immune thrombocytopenia,” Hematology, vol. 22, no. 1, pp. 41–53, 2017.
B. Zeller et al., “Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease,” Acta Paediatr., vol. 94, no. 2, pp. 178–184, 2005.
M. Thomas and V. S. Gallicchio, “The Cause and Effect of Immune Thrombocytopenia (ITP) on Individuals,” J Med-Clin Res Rev, vol. 7, no. 4, pp. 1–11, 2023.
D. Provan et al., “International consensus report on the investigation and management of primary immune thrombocytopenia,” Blood, J. Am. Soc. Hematol., vol. 115, no. 2, pp. 168–186, 2010.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Rawan Alaa
This work is licensed under a Creative Commons Attribution 4.0 International License.
